Licensing News: Breaking Licensing News, Comments and Articles.

Grifols signs $90.7m respiratory deal with Aradigm

Grifols has signed a worldwide licensing agreement worth up to $90.7m to develop and commercialize Aradigm's formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosi...

South Korea Pharmaceutical Market - Latest Industry Size, Share, Growth, Trends and Forecast Analysis Report 2013 Available at ResearchMoz.us

New market research report "South Korea Pharmaceutical Market Outlook 2013" added to its huge collection of research reports. Albany, NY (PRWEB) May 22, 2013 Researchmoz presents this most up-to-date research on South Korea Pharmaceutical Market Outlook 2013. The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the South Korea...

Ranbaxy Highlights Improved Business and Quality Assurance Standards

Dedicated to Providing Safe and Efficacious Medicines Globally Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) (“Ranbaxy”) today highlighted some of the major specific actions the Company has been taking in recent years to address certain conduct of the past and to ensure the safety and efficacy of all Ranbaxy products currently availabl...

Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors

NEW YORK, May 22, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of June S. Almenoff, M.D., Ph.D., to its Board of Directors. Dr. Almenoff has extensive experience in the pharmaceutical industry, working on early and late stage drug development. "We...

NICE must have access to evidence for pharma licensing decisions, says NAO

NICE must have access to evidence for pharma licensing decisions, says NAO

MRI Systems Market to 2018: Global Industry Analysis, Size, Share, Growth, Trends And Forecast Reseach Report Available at MarketResearchReports.biz

MarketResearchReports.Biz announces addition of new report “MRI Systems Market to 2018 - Technological advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth” to its database. Albany, NY (PRWEB) May 22, 2013 MRI Systems Market to 2018 Technological advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to...

TriStar Wellness Solutions Signs Exclusive Global Licensing Option Agreement With Polytherapeutics for Treatment of Specific Skin Conditions and Wound Care

PharmaDur® Drug Delivery Technology to Form Basis of Novel Treatments TriStar Wellness Solutions, Inc. (OTCQB: TWSI), a health and wellness company that targets opportunities in the self-care and professional marketplace, has signed an exclusive, three-year licensing option agreement with Polytherapeutics, Inc. for its PharmaDur® drug delivery...

New Online Vision Certification Service Streamlines the Driver’s License Renewal Process in Maryland

Electronic submissions of eye exam results help citizens skip the trip to the MVA The Maryland Motor Vehicle Administration (MVA) recently launched the Online Vision Certification Service to allow authorized vision providers to submit eye exam results electronically to the MVA. Vision providers can register to use the service at no charge through the s...

Edison Investment - e-Therapeutics Results update - Progress in development and discovery

e-Therapeutics has provided a comprehensive update of its development pipeline. ETS2101, for various solid tumours, is the major focus and is progressing through Phase I trials with encouraging early results. A proof-of concept study for the antidepressant ETS6103 is due to start shortly, with results expected in H214. The first new drug candidate to emerge from the newly bolstered discovery pla...

Edison Investment - Algeta - Investment summary - FDA go for Xofigo

The FDA’s approval of Xofigo for metastatic prostate cancer will trigger a €50m milestone to Algeta from partner Bayer in Q213. The broad label, early approval and premium pricing could result in upgrades to 2013 consensus sales forecasts. Despite this, we anticipate a measured commercial launch initially targeting US sites involved in the early access programme (EAP). Algeta’s...

Columbia University licenses 3D segmentation software to Varian

Columbia University has signed a licensing agreement with Varian Medical Systems for novel imaging software that facilitates 3D segmentation, the process by which anatomical structures in medical images are distinguished from one another—an importa...

Global Vision Text Comparison Software Docu-Proof Recognized by the EMA for Regulatory Submissions

MONTREAL, May 21, 2013 /PRNewswire/ -- Global Vision, the industry leader in the development of automated proofreading solutions, today announced that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency (EMA) for pharmaceutical companies using parallel distribution methods of medicinal products. For pharmaceutical companie...

Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™

Aradigm’s Proprietary Inhaled Ciprofloxacin Formulation is a Potential New Therapy for Patients with Severe Respiratory Disease Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) (“Grifols”) and Aradigm Corporation (OTC BB:ARDM.OB) (“Aradigm”) today announced the signing of an exclusive, worldwide license for Aradigm’s proprietary formulati...

Grifols Taking Aradigm Stake in Up To $116M Licensing Deal

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols, S.A. and Aradigm Corporation today announced the signing of an exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including...

Global Vision's Text Comparison Software Docu-Proof Recognized by the EMA for Regulatory Submissions

With Docu-Proof, Annual Update and Change Notification Fees Reduced By 50% Montreal, CANADA (PRWEB) May 21, 2013 Global Vision, the industry leader in the development of automated proofreading solutions, today announced that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency (EMA) for pharmaceutical companies using parallel distribut...

Stockholm Business Region: Exclusive Showcase at BioEquity Europe 2013 in Stockholm: Meet Stockholm’s Most Promising Life Science Companies

The 14th annual BioEquity Europe is being held in Stockholm tomorrow May 22nd 2013. The conference offers a unique possibility to meet companies listed on Stockholm-Uppsala Life Science Investment Hotlist during an exclusive showcase. The hotlist features carefully selected, investment-ready Stockholm-Uppsala based companies on the cutting edge of...

Pharmalicensing and Bionow sign strategic marketing and member benefit agreement

York, UK & Manchester, UK - May 20th, 2013 – Pharmalicensing, a division of IP Technology Exchange, Inc, today announced it has agreed a partnership with Bionow, the membership company representing the interests of life science organisation...

Safilo, Essilor in 10-year licensing deal

MILAN, May 21 (Reuters) - Italy's eyewear maker Safilo said on Tuesday it had agreed a 10-year licensing deal with France's Essilor, the world's biggest maker of corrective eye lenses.

Perry Ellis International Announces Licensing Agreement With Delta Galil for Original Penguin by Munsingwear Sleepwear and Underwear

MIAMI, May 21, 2013 (GLOBE NEWSWIRE) -- Perry Ellis International (PEI) (Nasdaq:PERY) announced today that it has entered into a license agreement with Delta Galil Industries USA, granting rights for Original Penguin by Munsingwear men's underwear and sleepwear for the U.S. and Canada. Original Penguin, one of the most recognizable brands in the PEI power portfolio, is known for its modern vintag...

Adeptia Announces New Release of Enterprise Business Integration Solution

Industry Leader Advances Next-generation Integration Solution with Key Performance, Usability and Enterprise-class Enhancements Chicago, IL (PRWEB) May 20, 2013 Adeptia Inc., a leading provider of innovative cloud and on-premise business process integration solutions, today announced the availability of version 6.0 of its next-generation integration solution. Version 6.0 is the only process-cent...

Vote Yes on F

LOS ANGELES, May 20, 2013 /PRNewswire/ -- On May 21 join Angelenos for Safe Access -  a coalition of business, collectives, doctors and patients - in voting Yes on F and No on D. Proposition D is a fraud that doesn't work.  Proposition D doesn't protect minors, patients or the public. Ordinance F is the solution to create sustainable and healthy rules that would - regulate medical...

Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth

NEW YORK, LONDON, BERLIN and PARIS, May 20, 2013 /PRNewswire/ -- Arthroscopy Devices Market to 2018 - Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Future Growth" looks at the market landscape, competitive landscape, and market trends for the six arthroscopy device market segments: arthroscopes, arthroscopy shavers, arthroscopy Fluid Management...

eFFECTOR Therapeutics Raises $45 Million in Series A Financing

SAN DIEGO, May 20, 2013 /PRNewswire/ -- eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing.  eFFECTOR is focused on inventing and developing small molecule drugs to selectively regulate protein synthesis, also known as translation, with an initial emphasis on cancer.  Series A investors include U.S. Ven...

Partnering with Pfizer: Collaborating to give hope

Pfizer is a top pharma company active in partnering, licensing and M&A in pharmaceuticals. Pfizer’s tag lines for partnering include: Partner-driven Join us in advancing our vision of a healthier world Partners welcome Advancing medical breakthroughs Collaborating to give hope Pfizer believes that working together is critical to harnessing innovative science. Pfizer seek strong, long-term...